nl 1

NL-1, a mitoNEET inhibitor, exhibits antileukemic effects.

Phenylbutazone (Butazolidine) is a butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ankylosing spondylitis, rheumatoid arthritis, and reactive arthritis.

Reparixin L-lysine salt (Repertaxin L-lysine salt) is an allosteric chemokine receptor 1/2 (CXCR1/2) activation inhibitor.

Inaxaplin is an apolipoprotein L1 ( APOL1 ) function inhibitor. Inaxaplin can be used for the research of kidney disease.

APOL1-IN-1 is a potent inhibitor of apolipoprotein L1 (APOL1) that can be used to study the pathogenesis of focal segmental glomerulosclerosis (FSGS) and nondiabetic kidney disease (NDKD), facilitating research into these diseases.

Reparixin (Repertaxin) is a potent inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemotaxis (IC50=1 nM).

GNF7156 is a potent and selective DYRK1A inhibitor.

ONL-1204 is a small molecule, CD95 antigen inhibitor (Fas inhibitor) being developed by ONL Therapeutics for the treatment of retinal detachment.

AM92016 is a specific blocker of the time dependent delayed rectifier potassium current. AM92016 does not show any β-adrenoceptor blocking activity.

NL-103 is a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations. NL-103 comprises structural elements of Hh pathway inhibitor vismodegib, and histone deacetylase (HDAC) inhibitor vorinostat. NL-103 simultaneously and significantly inhibited both HDACs and Hh pathway. Importantly, NL-103 effectively overcame vismodegib resistance induced by Smoothened point mutations. Moreover, NL-103 significantly downregulated the expression of Gli2 which plays an important role in Hh pathway. NL-103 may be a promising compound for clinical development as a more effective Hh pathway inhibitor.

NL13, a Polo-like kinase 4 (PLK4) inhibitor, exhibits an IC 50 value of 2.32 μM. It demonstrates the ability to suppress the viability of PC3 and DU145 prostate cancer cells with respective IC 50 values of 3.51 μM and 2.53 μM. NL13 also inhibits tumor growth in prostate cancer mice. Additionally, it deactivates the AKT signaling pathway by reducing CCNB1/CDK1 levels, leading to G2/M cell cycle arrest and initiating apoptosis through caspase-9/caspase-3 cleavage.

(-)-Gomisin L1 induces G2/M arrest and apoptosis in human ovarian cancer cells.

S1b3inL1 is a macrocylcic peptide inhibitor of the SARS-CoV-2 spike protein. It binds with high affinity to a conserved site on the spike protein, effectively suppressing the infection of various SARS-CoV-2 variants. S1b3inL1 exhibits antiviral activity.